Ling Chen

Dr. Ling Chen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 July 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QLQuanxian Liu
Quanxian Liu
LHLu Huang
Lu Huang
HYHong Yan
Hong Yan
ZZZhaojing Zong
Zhaojing Zong
ZCZhenyong Chen
Zhenyong Chen
YLYuanbo Lan
Yuanbo Lan
Objective: To analyze the clinical and laboratory characteristics and to identify predictors of moderate to severe anti-tuberculosis drug-induced liver injury (ATB-DILI) in patients with tuberculosis.Methods: This prospective study enrolled Tuberculosis (TB) patients treated with first-line anti-tuberculosis drugs at the Affiliated Hospital of Zunyi Medical University between May 2022 and June 2023. The occurrence of ATB-DILI was monitored, and demographic and clinical data were gathered. We analyzed risk factors for the development of moderate to severe ATB-DILI.Results: ATB-DILI was detected in 120 (10.7%) of the patients, with moderate to severe ATB-DILI occurring in 23 (2.0%) of the 1,124 patients treated with anti-tuberculosis treatment. Multivariate cox regression analysis identified malnutrition (HR = 4.564, 95% CI: 1.029–20.251, p = 0.046) and hemoglobin levels <120 g/L (HR = 2.825, 95% CI: 1.268–11.540, p = 0.017) as independent risk factors for moderate to severe ATB-DILI.Conclusion: The incidence of moderate to severe ATB-DILI was found to be 2.0%. Malnutrition and hemoglobin levels below 120 g/L emerged as significant independent risk factors for the occurrence of moderate to severe ATB-DILI in this patient population.

27 March 2020 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
ZPZhangli Peng
Zhangli Peng
LCLing Chen
Ling Chen
HZHong Zhang
Hong Zhang
Objective: Serum proteomic analysis of tuberculosis (TB) antigens to identify biomarkers enabling discrimination of active TB (ATB) from latent TB infection (LTBI). Methods: Serum samples from patients with ATB, individuals with LTBI and healthy controls (HCs) were used to probe proteome microarrays. Based on signal intensities of IgG and IgM antibodies, 100 TB proteins were selected for fabrication of mini-protein microarrays, which were then used to screen 204 serum samples. Results: Proteome microarray analyses showed that 58 IgG or IgM specific antibodies were significantly more abundant in ATB patients than in individuals with LTBI or HCs. Serological evaluation of mini-protein microarrays demonstrated that average levels of 15 specific antibodies were higher in ATB patients than in individuals with LTBI or HCs. This combination of 15 TB serum biomarkers had a sensitivity of 85.4% and specificity of 90.3% in discriminating ATB from LTBI. Conclusion: Combinations of serum biomarkers can offer improved diagnostic performance in discriminating ATB from LTBI. Five biomarkers (MT1560.1, Rv0049, Rv0270, Rv1597 and Rv3480c) associated with ATB induced stronger IgM responses in these patients.

1 January 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YLYuanbo Lan
Yuanbo Lan
YLYuqin Li
Yuqin Li
LCLing Chen
Ling Chen
JZJianyong Zhang
Jianyong Zhang
HZHong Zhang
Hong Zhang
Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China Yuanbo Lan,1,* Yuqin Li,1,* Ling Chen,1 Jianyong Zhang,1 Hong Zhang1,2 1Department of Respiratory Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563003, China; 2Z-BioMed, Inc., Rockville, MD 20855, USA *These authors contributed equally to this work Objectives: Tuberculosis (TB) is the leading cause of death from infectious diseases in the world, with an estimated 1.6 million deaths from TB in 2017. The objectives of this study were to determine drug resistance profiles of Mycobacterium tuberculosis clinical isolates and to analyze the trends in drug-resistant and multidrug-resistant tuberculosis (MDR-TB) from 2008 to 2015 at a major hospital in Guizhou, a high-TB burden and resource-limited province of China. Patients and methods: A total of 462 clinical isolates were collected from patients with pulmonary TB during the period from January 2013 to December 2015 and used for determining drug resistance profiles against four first-line and six second-line anti-TB drugs, and the results were compared with those of two previous studies. Results: Exactly 4.4% of new and 44.1% of previously treated TB cases were MDR/rifampicin-resistant TB (RR-TB), which were higher than the 2017 global average numbers of 3.5% and 18%, respectively. There were many drug-resistant patterns among MDR-TB isolates and most of them were resistant to three or four anti-TB drugs. The trends in drug-resistant and MDR-TB declined at the hospital from 2008 to 2015. Conclusion: Results of this study show that the prevalence of MDR/RR-TB at a major hospital in Guizhou is higher than the global average and confirm the existence of heterogeneity in drug resistance patterns of MDR-TB isolates. Additionally, three practical measures have played an important role in the overall decline of MDR-TB at the hospital from 2008 to 2015. Keywords: Mycobacterium tuberculosis, anti-TB drugs, drug resistance patterns, trends

1 November 2018 in The Journal of Alternative and Complementary Medicine
Verified
Journal Article
Closed access
LXLian Xiong
Lian Xiong
LCLing Chen
Ling Chen
CWChengqiong Wang
Chengqiong Wang
JYJianbo Yue
Jianbo Yue
YLYuqin Li
Yuqin Li
ZXZheng Xiao
Zheng Xiao
Background: Tanreqing injection (TRQ) is often used in the treatment of pulmonary infection in patients with tuberculosis (TB). But its efficacy and safety are still unclear; to further reveal its efficacy and safety, the authors systematically evaluated all relevant trials. Methods: The authors searched published trials using the search strategy as (Tanreqing OR “Tanreqing injection”) AND (“Tuberculosis” [MeSH] OR Tuberculosis OR TB) in Embase, PubMed, CNKI, VIP, Wanfang Database, CBM and CENTRAL, and ongoing trials in Chinese and U.S. clinical trials and World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP) (established to January 2017). The authors evaluated the methodological bias risk of all included trials using the Cochrane evaluation handbook of randomized controlled trials (RCTs) (5.1.0), extracted data following the PICO principles, and synthesized the data using meta-analysis. Results: Twenty-six RCTs involving 2404 patients were included. In TRQ alone versus antibiotics, the merged risk ratio (RR) values and their confidence interval (95% CI) of meta-analysis for overall efficacy, lesion absorption, and bacterial clearance were as follows: 1.05 (0.99–1.10), 0.98 (0.89–1.08), and 1.36 (1.09–1.70). All differences were not statistically significant. In TRQ plus antibiotics versus antibiotics, the RR values and their 95% CI of overall efficacy, lesion absorption, and bacterial clearance were as follows: 1.17 (1.10–1.25), 1.24 (1.11–1.38), and 1.61 (1.36–1.90). All differences were statistically significant. Except for the bacterial clearance, sensitivity analyses showed that the overall efficacy had good stability. Conclusions: TRQ may have the same overall efficacy as antibiotics in pulmonary infection in patients with TB. TRQ plus antibiotics may improve the clinical efficacy. TRQ may have synergistic effect to antibiotics through bacteriostatic activity and eliminating inflammatory mediators. Its antibacterial activity may be better than some antibiotics and does not increase adverse drug reaction. But all these need new evidences for further investigation.

1 September 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
ZCZhimin Cao
Zhimin Cao
YLYuanbo Lan
Yuanbo Lan
LCLing Chen
Ling Chen
MXMin Xiang
Min Xiang
ZPZhiyuan Peng
Zhiyuan Peng
HZHong Zhang
Hong Zhang
Background: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four first-line anti-TB drugs as well as treatment history in clinical isolates of Mycobacterium tuberculosis. Patients and methods: M. tuberculosis clinical isolates were collected from 318 in-patients with smear-positive TB between October 2008 and September 2016 at a major hospital in Zunyi, Guizhou Province of China, and used for drug susceptibility testing against four first-line anti-TB drugs. Genomic DNA extracted from clinical isolates was used for PCR amplification and DNA sequencing of the pncA gene. Results: Among 318 clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to rifampicin, isoniazid, ethambutol and streptomycin respectively. In addition, 124 clinical isolates were MDR-TB and 71.8% of them were previously treated cases. Sequencing results showed that 46.8% of MDR-TB and 2.2% of drug susceptible isolates harbored a pncA mutation, and 52 types of pncA mutations were detected from 64 isolates. The prevalence of pncA mutations in isolates resistant to first-line anti-TB drugs and previously treated TB cases was significantly higher than that in drug-susceptible isolates and new cases of TB. Conclusion: High prevalence of pncA mutations in clinical isolates of M. tuberculosis from Zunyi, Guizhou Province of China, is correlated with resistance to four first-line anti-TB drugs, MDR-TB and previously treated TB cases.